Showing 1451-1460 of 1662 results for "".
Creating Loyal Patients
https://practicaldermatology.com/topics/practice-management/creating-loyal-patients/21360/A look at current research and best practices.How To Protect Against Losing Assets In A Divorce
https://practicaldermatology.com/topics/practice-management/how-to-protect-against-losing-assets-in-a-divorce/21399/Tips for minimizing potential financial pain from a marital split.Employee Engagement: A Key Success Factor in the Workplace
https://practicaldermatology.com/topics/practice-management/employee-engagement-a-key-success-factor-in-the-workplace/21387/Tips for increasing productivity and satisfaction among staff.Tips for Increasing Practice Efficiency
https://practicaldermatology.com/topics/practice-management/tips-for-increasing-practice-efficiency/21405/How to stay on schedule and keep patients, staff, and physicians happy.Analyzing Risk Factors for Subsequent Primary Melanomas
https://practicaldermatology.com/topics/skin-cancer-photoprotection/analyzing-risk-factors-for-subsequent-primary-melanomas/21429/Therapeutics Focus: Corticosteroids
https://practicaldermatology.com/topics/psoriasis/therapeutics-focus-corticosteroids/21432/New products and pharmacologic developmentsGoogle Authorship Can Boost a Dermatologist's Online Profile
https://practicaldermatology.com/topics/practice-management/google-authorship-can-boost-a-dermatologists-online-profile/21437/Scurvy in the Modern Era
https://practicaldermatology.com/topics/general-topics/scurvy-in-the-modern-era/21456/One of the winning presentations given by dermatology residents at Cosmetic Surgery Forum.Charging Toward Stage 2 of Meaningful Use
https://practicaldermatology.com/topics/practice-management/charging-toward-stage-2-of-meaningful-use/21467/As the next stage of the Federal EHR incentive program is set to begin, the forecast remains uncertain.Weighing the Prospects of Biosimilars
https://practicaldermatology.com/columns/clinical-focus-1/weighing-the-prospects-of-biosimilars/21477/If they are found to be comparable to the “originators,” biosimilar agents may offer patients significant therapeutic benefits as well as cost efficiency.